Prot #NIT-106 (ION-02): A Phase 1b/2a, Open Label Study to Evaluate Anti-Tumor Efficacy and Safety of rhIL-7-hyFc (NT-I7) in Combination with Anti-PD-L1 (Atezolizumab) in Patients with Anti-PD-1/PD-L1 Naïve or Relapsed/Refractory High-Risk Skin Cancers

Project: Research project

Project Details

StatusActive
Effective start/end date10/14/2010/14/23

Funding

  • Fred Hutchinson Cancer Research Center (Prot #NIT-106 (ION-02))
  • NeoImmuneTech, Inc. (Prot #NIT-106 (ION-02))